“Focus on…” session: monoclonal antibodies

141 LYMHPHA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION

O. E. Yt1, D. Torfoss1, O. Hungnes2, B. Ostenstad1, R. Evanger2, K. Wader4, T. Nordby5, H. Waakkan1, S. G. Dudman6, P. Meyer6, A. Kolstad1

1Dep of Oncology, Oslo University Hospital, Oslo, Norway, 2Dep of Virology, Norwegian Inst of Public Health, Oslo, Norway, 3Dep of Oncology, Haukeland University Hospital, Bergen, Norway, 4Dep of Oncology, St Olav’s Hospital, Trondheim, Norway, 5Dep of Oncology, University Hospital of Northen Norway, Tromsø, Norway, 6Dep of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway

Background: Rapid and prolonged depletion of normal B cells is observed in lymphoma patients treated with rituximab-containing regimens. This may preclude normal immune responses to vaccines. We have previously shown that patients receiving chemotherapy without rituximab can get serological responses to influenza vaccination. In light of the H1N1-epidemic in 2009, we aimed to investigate the immune response to the H1N1 influenza A-vaccine in lymphoma patients treated with chemotherapy in combination with rituximab (R-chemo) or rituximab alone (R-single).

Material and Methods: Lymphoma patients receiving R-chemo or R-single therapy within the last 6 months before vaccination with the H1N1-vaccine were included. Healthy volunteers taking the vaccination served as control group. In blood samples taken immediately before (pre-sample) and at least 3 weeks after vaccination (post-sample), antibody titers were determined using the hemagglutination-inhibition test.

Results: Post-samples in 72 patients (68 non-Hodgkins lymphoma) and 89 controls were analyzed for serological response. We excluded 4 patients and 36 controls with a pre-sample antibody titer ≥ 40, indicating possible infection before vaccination. Thus, 68 patients and 53 controls were included in the final analysis. No patients compared to VS “WATCH AND WAIT” RITUXIMAB IN ASYMPTOMATIC, NON-BULKY FOLLICULAR LYMPHOMA: RESULTS FROM INTERGROUP TRIAL OF RITUXIMAB VS “WATCH AND WAIT”

L. Lowry1, M. Pule1, K. Ardeshr2, W. Qian3, P. Smith4, C. Pocock5, M. Fial1, D. Cunningham6, J. Davies1, K. Bradstock7, D. C. Linch1

1Haematology, UCL, London, United Kingdom, 2Haematology, UCLH, London, United Kingdom, 3Clinical Trials Unit, MRC, London, United Kingdom, 4Cancer Trials, CRUK & UCL, London, United Kingdom, 5Haematology, Kent & Canterbury Hospital, Canterbury, United Kingdom, 6Haematology, Leicester Royal Infirmary, Leicester, United Kingdom, 7Oncology, Royal Marsden Hospital, London, United Kingdom, 8Haematology, Western General Hospital, Edinburgh, United Kingdom, 9Haematology, Westmead Hospital, Sydney, Australia

Introduction: It has been suggested that polymorphism of Fc receptors (FcγR), particularly FcγRIIa, influence response to rituximab (R) although this has not been found in all series. The discrepancies may result in part from small series sizes, different types of lymphoma, and the use of non-specific markers such as cytotoxics. The ‘Watch and Wait’ trial comparing R alone vs watchful waiting (W&W) in patients with asymptomatic non-bulky follicular lymphoma (NFLH) provides an opportunity to assess the impact of FcγR polymorphisms on a larger patient cohort.

Materials and Methods: Patients were treated with W&W, 4 infusions of R 375mg/m2 at weekly intervals (R4) or R followed by R maintenance 375mg/m2 2 monthly for 2 years (R4M). Response to treatment was assessed at 7 and 13 months. Three polymorphisms were ascertained FcγRIIa V158F, FcγRIIa H131R and FcγRIIb 123T.

Results: In total 276 patients received R and DNA is available on 257 of them. When considering all patients who also received R, the polymorphism achieving CR or CRu at either time point was not significantly influenced by any of the FcγR polymorphisms, nor were there significant differences in time to next treatment or progression free survival.

Further analyses explored the impact of R maintenance. R4+M patients (n=175) had significantly higher CR/CRu rate and significantly fewer events than R4 (n=75). There was no significant interaction for the FcγRIIIa or FcγRIIb polymorphisms, although it did appear that patients with the FcγRIIa HH genotype have a better PFS response to maintenance R. This, however, was largely based on a high event rate in the 10 HH patients who only received R4, rather than a low event rate in those receiving R4+M.

Conclusions: The finding that FcγRIIIa polymorphisms do not influence the response to R+4 in NFLH may have relevance to the design of next generation CD20 antibodies. No impact of FcγRIIa polymorphisms was seen in those just receiving R4 but the relatively small number of patients in this arm (n=79) limits firm conclusions.

143 FC GAMMA RECEPTOR IIB ON HUMAN B CELLS PROMOTES RITUXIMAB INTERNALIZATION AND REDUCES CLINICAL EFFICACY

S. H. Lim1, A. Vaughan1, R. F. French1, S. A. Beers1, O. H. Chan1, E. Williams1, S. V. Dixon1, K. Potter1, I. Mockridge1, M. Ashton-Key1, A. J. Davies1, D. G. Oscier1, P. W. Johnson1, M. J. Glennie1, M. S. Craig1

1Cancer Sciences Division, University of Southampton, Southampton, United Kingdom, 2Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom

Introduction: The anti-CD20 monoclonal antibody (mAb) rituximab is invaluable in the treatment of B-cell neoplasms and resistance remains a significant problem. Anti-CD20 mAb can be classified as type I (rituximab, ofatumumab) or type II (tositumomab, GA101) according to their activities in various in vitro effector assays. We recently reported that type I mAb, unlike type II, are internalised from the surface of normal and malignant B cells. Such internalisation is important because it consumes mAb and reduces therapeutic efficacy. Here, we report that the inhibitory Fc gamma receptor (FcγRIIb) on target B-cells is a key regulator of this process.

Material and Methods: Internalisation of anti-CD20 mAb in primary tumour material is analysed using an in vitro flow cytometry-based fluorescence quenching assay. Western blotting and confocal microscopy are used to elucidate the events post-internalisation.

Results: Rapid internalisation was particularly evident in most cases of chronic lymphocytic leukaemia and mantle cell lymphoma (MCL), but not from the majority of follicular or diffuse large B-cell lymphomas, possibly explaining their differing clinical responses to rituximab. Within each disease, the speed and extent of internalisation was heterogeneous. Internalisation of rituximab correlated strongly with FcγRIIb expression on tumour cells regardless of lymphoma subtype. Transfection of FcγRIIb converted FcγRIIb Ramos cells into rapid internalisers in a dose-dependent manner. Internalisation also resulted in reduced macrophage phagocytosis of mAb-coated targets and could be inhibited by blocking FcγRIIb.

Conclusions: High FcγRIIb expression provides a potential biomarker of response to rituximab-containing therapy and may identify patients for which treatment with type II anti-CD20 mAb may be preferable.

144 RESULTS FROM A PHASE II STUDY (BO20999) OF ROSO72759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGGIN'S LYMPHOMA

G. Cartron1, G. Thebemont2, P. Solal-Celigny3, F. Morschhauser4, C. Haour5, R. Bouabdallah6, M. Wenger7, G. Salles8

1Hematology-Oncology, University Hospital, Montpellier, France, 2Hematology-Oncology, Hopital Henri Mondor, Creteil, France, 3Hematologie, Institut Paoli Calmettes, Marseille, France, 4Hematologie, Hospices Civils de Lyon - Universite de Lyon, Lyon, France

Background: GA101 is a type I, glycoengineered, humanized monoclonal anti-CD20 antibody currently in clinical trials.

Methods: Forty patients with CD20+ aggressive lymphoma (aNHL) were randomized to receive GA101 in a low-dose (LD, n=21 [10 DLBCL/11 MCL]) or a high dose (HD, n=19 [15 DLBCL/4 MCL]) cohort. GA101 monotherapy was given on d1, d8, d22 and q21 days for total of 9 infusions. In the LD cohort, GA101 was given 400mg all infusions; in the HD cohort, d1 and d8 at 1600mg and 800mg thereafter. Primary
Endpoint was end of treatment response (EOR), assessed 4 weeks after last infusion. Secondary objectives included safety and pharmacokinetics.

**Results:** End of treatment response (EOR) was 24% (5/21) in the LD cohort and 32% (6/19) in the HD cohort. For DLBCL patients EOR was 28% and for MCL patients EOR was 27%. Of 13 refractory patients in LD, 1 patient achieved PR (8%) and of 12 refractory patients in HD, 3 patients achieved PR (25%). The most common AEs were G1-2 infusion related reactions (LD 81%, HD 68% of patients). Fourteen patients experienced at least one SAE during treatment period (LD=9, HD=5), with 7 related to GA101 (LD n=5, HD n=2), and 5 of these events associated with the first infusion (IRR=3; TLS=2), one after day 8 infusion (pyrexia), and one after cycle 6 infusion (bradycardia). During treatment, related G3-4 hematological AEs were transient neutropenia (n = 1 in HD), anemia (n = 2 in LD) and thrombocytopenia (n = 3 in LD). Ten patients had at least one G1-2 infection (5 in each cohort) with no G3-4 infections reported. GA101 plasma profiles were explored reflecting that mantle cell lymphoma patients in the HD (n=4) and LD (n=10) appeared to show lower plasma concentrations compared to DLBCL patients. There were 17 patient deaths reported (LD=11, HD=6), with 14 due to PD and 3 due to AE (1 during treatment period; cardio-respiratory arrest; not GA101-related).

**Conclusions:** GA101 monotherapy is well tolerated showing promising efficacy in heavily pre-treated aggressive NHL patients. Trials are currently ongoing exploring GA101 in combination with chemotherapy.

145 A PHASE 2B TRIAL COMPARING DACETUZUMAB + R-ICE VS PLACEBO + R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA


1Lymphoma/Myeloma, MD Anderson Cancer Ctr, Houston, United States, 2Hematology, Mayo Clinic, Rochester, United States, 3Onc, Stanford Cancer Ctr, Stanford, United States, 4Heme/Onc, Ctr Hospitalier Lyon Sud, Pierre Benite, France, 5Onc, Wash Univ School of Med, St Louis, United States, 6Heme/Onc, Med Univ of South Carolina, Charleston, United States, 7Heme/Onc, Univ of Alabama, Birmingham, United States, 8Hematology, Samodzielny Publiczny Szpital Kliniczny, Wroclaw, Poland, 9Trans Med, Seattle Genetics Inc, Bothell, United States

**Background:** Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody that mediates antitumor activity via multiple mechanisms of action, has demonstrated modest single-agent activity in DLBCL in prior phase 1 and 2 trials.

**Methods:** A phase 2b, double-blind, placebo-controlled trial compared efficacy and safety of 3 cycles of R-ICE + dacetuzumab (8 mg/kg) vs R-ICE + placebo in DLBCL patients (pts) who failed prior R-CHOP. Primary endpoint was CR; response was assessed by CT/PET. Additional endpoints include failure-free survival (FFS) and overall survival (OS).

**Results:** A total of 151 pts (median age 59, range 22–74) were randomized in 10 countries. There were no notable differences in demographics, completion of planned therapy, stem cell collection or subsequent autologous stem cell transplant (ASCT) between arms. AEs were more common in dacetuzumab pts. Among pts who underwent ASCT the survival (OS) advantage with dacetuzumab is statistically significant (HR=0.167, p=0.008). Fewer deaths have occurred in pts who received dacetuzumab vs placebo (40% vs 50% respectively) with a 14% reduction in death due to disease progression (25% vs 39% respectively).

**Conclusions:** Dacetuzumab can be safely combined with R-ICE without compromising stem cell collection in pts with DLBCL who previously failed R-CHOP. Data suggest that this combination may improve FFS and OS. The improved OS, despite no improvement in the CR rate, may be explained by the potential immunomodulatory effect of a partially agonistic CD40 antibody. Additional survival data are being collected to guide future development decisions.